to Oslo Medtech
Register here to subscribe to our newsletter!
Oslo Medtech latest newsletter (May 2013)
Interested in previous newsletters? Click here
Generating innovation. For better living and health.
iSentio AS has raised 1.5 million USD in new funding from new and existing investors. The main new investor is Sarsia Seed AS, a Norwegian seed capital fund which invests in early phase technology companies within energy / cleantech and Life Science sectors.
Curvus Announces 510(K) Clearance of its Completely Wireless Arrhythmia Monitoring Device.
Borge Bogaard, Chief Executive Officer of Curvus, said, "We are thrilled that Curvus has achieved regulatory clearance and can now be commercialized in the US. Due to the rapidly increasing burden of atrial fibrillation worldwide, we believe that expanded monitoring and diagnosis of these cardiac events combined with the release of several new anticoagulant drugs, will make a major contribution to control the disastrous worldwide burden of stroke. With its 100% wireless design and ability to transmit clear, actionable data whether the patient is resting, running a marathon or showering, we believe Curvus is well-positioned to expand monitoring broadly."
ENIAC Joint Undertaking (www. Eniac.eu) will issue the fourth call for proposals in spring 2011, and new project ideas will be discussed at a brookerage event in Berlin 1-2 February. ENIAC JU is funding research within nanoelectronics including sensors, and one of the application areas is “Health and the Aging Society”. The 2011 call will focus on “Home Healthcare” and “Hospital Healthcare”.
OstomyCure AS, a company focused on developing novel products for stoma patients, announces that it has appointed Geir Christian Melen as its Chief Executive Officer (CEO). At OstomyCure, Mr. Melen will be responsible for the development and commercialization of TIES®, a proprietary implant system focused on dramatically improving the lives of stoma patients. "I look forward to joining OstomyCure at a time of great potential", Geir Christian Melen commented. - OstomyCure has embarked on the clinical development phase for TIES® and I believe this new medical device can be brought successfully to market on an international basis.